7/29/2019 Cancer and the Immune System_BS963_EK
1/44
Cancer and the immune system
BS963
Elena Klenova, e-mail:[email protected]
7/29/2019 Cancer and the Immune System_BS963_EK
2/44
Immunobiology : the immune system in health and disease
/Charles A. Janeway, Paul Travers, Mark Walport and Mark Shlomchik; 2005,
Garland Science Publishing
Janeway's immunobiology 7th ed. / Kenneth Murphy, Paul Travers, Mark
Walport ; with contributions by Michael Ehrenstein ... [et al.]; 2009, Garland
Science Publishing
The Immune system/Peter Parham, 2005, Garland Science Publishing
Cellular and molecular immunology / Abul K. Abbas, Andrew H. Lichtman,Shiv Pillai/ 2007, Philadelphia : Saunders Elsevier ( also the 2005 Edition)
Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and
cancer immunoediting.Nature Reviews Immunology 2006, 6:836-848.
Ichim, C.V. Revisiting immunosurveillance and immunostimulation:
Implications for cancer immunotherapy J Transl Med 3, 8 (2005). Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev.
Immunol. 2003, 21:807-39
Smyth, M. J. et al. A fresh look at tumor immunosurveillance and
immunotherapy. Nature Immunology 2001, 2: 293 299.
Recommended reading
7/29/2019 Cancer and the Immune System_BS963_EK
3/44
Plan of the seminar
1. General Introduction ( Cancer and Immune system).2. Theories of the role of the immune system in cancer.
3. Cells of the immune system involved in anti-tumour
response and basic mechanisms of anti-tumourimmunity.
4. Tumours antigens: novel or over-expressed proteins
produced by tumours that may be recognized by the
immune system.
5. How do tumour cells escape from the immune
system?
6. Anti-tumour therapy. Anti-tumour vaccines.
7/29/2019 Cancer and the Immune System_BS963_EK
4/44
1. General Introduction ( Cancer
and Immune system).
7/29/2019 Cancer and the Immune System_BS963_EK
5/44
Cancer
Uncontrolled growth produces a tumour
( neoplasm).
Benign - a tumour that is not capable of
indefinite growth. It does not kill the host.
Malignant - a tumour that grows
indefinitely and often spreads (metastasis).
It can kill the host.
7/29/2019 Cancer and the Immune System_BS963_EK
6/44
Types of Cancer
(based on the type of affected tissue)
Carcinoma: Cancer of endo or ectoderm e.g.
Skin or epithelial lining of organs.
Sarcomas: Cancer of mesoderm e.g. bone.
Leukemias and Lymphomas: Cancers of
hematopoietic cells
7/29/2019 Cancer and the Immune System_BS963_EK
7/44
The Immune System
Innate (non-specific) immune
system (Granulocytes, Macrophages)
immediately available for combat
Adaptive (specific) immune system(T and B-Lymphocytes)
Production of antibody (Ab) or cells
specific to combat a particular antigen
7/29/2019 Cancer and the Immune System_BS963_EK
8/44
Innate and adaptive responses work together
Innate
Antigen independent
Immediate (hours)
Neutrophils
NK (Natural Killer) cells
Macrophages
Adaptive
Antigen-dependentSlower (days)
T cells
B cells
Dendritic cells a link between the innate and adaptive systems!
Innate immune responses help form adaptive immune
responses, and
Adaptive immune responses utilize the machinery of innate
immunity for effector function
7/29/2019 Cancer and the Immune System_BS963_EK
9/44
Evidence for the role of immune system in
tumor rejection
Spontaneous regression Regression of metastases after removal of
primary tumor
Regression after chemotherapy
Infiltration of tumors by lymphocytes andmacrophages
Lymphocyte proliferation in draining lymph
nodes
Higher incidence of cancer afterimmunosuppression/immunodeficiency (AIDS,
neonates, aged, transplant patients)
7/29/2019 Cancer and the Immune System_BS963_EK
10/44
Tumour rejection antigens are specific for
individual tumours
7/29/2019 Cancer and the Immune System_BS963_EK
11/44
2. Theories of the role of the
immune system in cancer.
7/29/2019 Cancer and the Immune System_BS963_EK
12/44
Two distinct theories of the role
of the immune system in cancer
Immunosurveillance - the tumour-
suppressing role of the immune system.
Immunostimulation - the tumour-
promoting role of the immune system.
Tumour and immune system interact:
mutual influence!
7/29/2019 Cancer and the Immune System_BS963_EK
13/44
Immunosurveillance (immune
surveillance ) As early as 1909 Paul Ehrlich postulated that
cancer occurs spontaneously in vivo and that the
immune system is able to both recognize and protect
against it . In the late 1950s Lewis Thomas introduced the theory
of immunosurveillance, which was subsequently
developed by Sir MacFarlane Burnet .
The theory states that immunosurveillance is aphysiologic function of the immune system. Cancerous
cells seen as foreign and thus can be constantly
eliminated by immune surveillance.Ichim, C.V. J Transl Med3, 8 (2005).
7/29/2019 Cancer and the Immune System_BS963_EK
14/44
Cancer immunosurveilance: evidence in humans
Increased incidence of virally-induced tumours in
Immunosuppressed patients
Studies showing increase in de novo malignant
melanoma in organs transplant patients
25-fold increase in incidence of lung
carcinoma in cardiac transplant patients
Reverse correlations between tumour infiltrating
lymphocytes and tumour survival
Dunn et al. Nature Reviews Immunology6, 836
848(2006)
l d
7/29/2019 Cancer and the Immune System_BS963_EK
15/44Dunn et al. Nature Reviews Immunology6, 836848 (2006)
Cancer immunosurveilance: evidence in mice
7/29/2019 Cancer and the Immune System_BS963_EK
16/44
Immunostimulation (immune stimulation)
The proof of the principle that an inappropriate type of
immune response will enhance tumour growth wasdemonstrated as early as 1907 by Flexner and Jobling,
who showed that injection of dead autologous tumour
cells enhanced the growth of pre-existing tumours.
In 1972, Richmond Prehn formulated the theory of
immunostimulation of tumour growth. This theory states
that, in contrast to the strong immune responsegenerated by transplantable tumours, a quantitatively
mild immune response, such as that generated by
spontaneous tumors, is stimulatory to the growth of
neoplasia.
7/29/2019 Cancer and the Immune System_BS963_EK
17/44
How the conflicting roles of the immune
response in neoplasia can be explained?
Modern view: The immune system is not a singleentity, but a complex system of constituents. The
concept of immunosurveillance has been modified
and is now considered in three phases:1. Elimination phase - recognition and
destruction of the tumour cells
2. Equilibrium phase occurs if elimination is
not successful. Tumour cells undergo changes in
a process called immunoediting.
3. Escape phase- tumour cells evolved enough
to grow unimpeded and form a tumour
7/29/2019 Cancer and the Immune System_BS963_EK
18/44
3. Cells of the immune systeminvolved in anti-tumour response
and basic mechanisms of anti-
tumour immunity.
7/29/2019 Cancer and the Immune System_BS963_EK
19/44
The immune system provides one of the body's main
defenses against cancer.
When normal cells turn into cancer cells, some of the antigenson their surface change.
These new or altered antigens flag immune defenders,
including cytotoxic T cells, natural killer cells, and macrophages.
Natural
IFN-g
IFN-g
7/29/2019 Cancer and the Immune System_BS963_EK
20/44
Immune cells are generated during hematopoiesis
C ll f h i i l d i
7/29/2019 Cancer and the Immune System_BS963_EK
21/44
Functions:
Phagocytosis
Antigen presentation to T cells
Phagocytosis of microorganisms and
antigen presentation to T cells
Kill tumor and virus-infected cells
Regulates humoral and
cell-mediated immune responses
Cells of the immune system involved in tumour response
7/29/2019 Cancer and the Immune System_BS963_EK
22/44
T-cell classification
Classification is based on the Structure & antigen specificity of TCR (T-cell receptor)
T cells are divided into two major groups: CD4+ T-helper and CD8+ T-cytotoxic cells.
The differentiation of T cells into CD4 vs. CD8 occurs during their development in the thymus.
T cells: CD 4 & 8 Accessory Molecules
CD4 + helper T cells (TH); further subdivided into type 1 and type 2, also known as Th1 and Th2. The
differentiation of Th cells into Th1 and Th2 occurs only after these cells have been activated during
an immune response, in the peripheral lymphoid system.
- Only recognize antigen bound to MHC class II molecule
CD 8 + cytotoxic T cells (TC)
-Only recognize antigen bound to MHC class I molecules
T cells require two signals for activation:
1 -from TCR /MHC-antigen complex & CD4 or CD8/MHC complex
2-from an accessory molecule CD28
When all appropriate signals are received, T-cells clonally expand as a result of IL-2 secretion forming
a population of T-cells with the same antigen specificity----further differentiation into memory
& effector cells
MHC M j Hi t tibilit C l R l f MHC M l l
7/29/2019 Cancer and the Immune System_BS963_EK
23/44
Membrane-bound glycoproteins
- Class I and Class II MHC molecules
- MHC genes highly polymorphic-within eachspecies there are many
different forms (alleles)
MHC function as antigen-recognition
molecules
- Can bind to a spectrum of antigenic peptides;polymorphism allows
for diversity in antigen recognition
MHC I ---expressed on all nucleated cells
- Present endogenous antigens
-CD 8 + (Tc cells) -recognize antigen on MHC I
MHC II ---expressed on Antigen presenting
cells (APC)
- Present exogenous antigen
- CD 4 + (Th cells) -recognize antigen on MHC II
MHC-Major Histocompatibility Complex: Role of MHC Molecules
7/29/2019 Cancer and the Immune System_BS963_EK
24/44
Anti-tumour immunity: basic
mechanisms
Immunology 7th Ed
( D. Male et al)
7/29/2019 Cancer and the Immune System_BS963_EK
25/44
Antigen presenting cells (APC)
Dendritic Cells (DC)
DCs are the interface between innate and adaptiveimmunity
DCs are immature as they circulate waiting toencounter pathogens. At this point, they are highly
phagocytic, but not good stimulators of adaptive T cellresponses
Once they are activated, they secrete cytokines toinitiate inflammation and then they migrate to lymph
nodes and mature As mature DCs they are very efficient APCs for T cell
stimulation
Other APCs: macrophages, neutrophils, B-
lymphocytes, monocytes.
7/29/2019 Cancer and the Immune System_BS963_EK
26/44
Anti-tumour immunity: basic mechanisms
Smyth, M. J. et al. Nature Immunology 2, 293 - 299 (2001)
Presence of tumour cells
and tumour antigens may
initiate the release ofdanger signals; cytokines,
heat shock proteins (HSP),
uric acid etc.
Activation and maturation
of dendritic cells, which
present tumour antigens to
CD8 and CD4 cells
Clonal expansion of CD8 and
CD4 T cells; migration fromthe lymph node
Subsequent T cell mediated
destruction of tumour cells
7/29/2019 Cancer and the Immune System_BS963_EK
27/44
The cellular basis of tumour immunology: CTL - tumor cell interactions
7/29/2019 Cancer and the Immune System_BS963_EK
28/44
Antigen presentation by antigen presenting cells
N t l Kill (NK) C ll
7/29/2019 Cancer and the Immune System_BS963_EK
29/44
Natural Killer (NK) Cells- First identified by having the ability to lytically kill certain
tumor cell lines without prior sensitization
- Kill target cell by release of cytotoxic granules containinggranzymes and perforin which penetrate target cellmembrane and induce programmed cell death
- Can mediate Antibody-Dependent Cellular Cytotoxicity(ADCC); (mechanism of immunologic lysis in whichcellular targets sensitized by specific antibodies areefficiently and selectively lysed by nonspecific effectors)
- Kill virally-infected cells with missing MHC class I
- Activated by IFN-a/b or IL-12 (produced rapidly byactivated macrophages)
- Activated NK cells secrete IFNg, acts on macrophages toincrease microbial phagocytosis and killing
Fig 8-3
7/29/2019 Cancer and the Immune System_BS963_EK
30/44
Basic facts about NK cells
They get easily activated, do not adapt and kill MHC-negative cells.
7/29/2019 Cancer and the Immune System_BS963_EK
31/44
4. Tumours antigens: novel or over-expressed
proteins produced by tumours that may be
recognized by the immune system.
7/29/2019 Cancer and the Immune System_BS963_EK
32/44
Major Histocompatability Complex antigens
TSTA
TATA
TSTA: unique to a tumourPlay an important role in tumor rejection.
TATA: shared by normal and tumour cells
Tumour-associated developmental Ag (TADA)
Tumour-associated viral Ag (TAVA)
Tumour-specific
transplantation Ag
Tumour-associated
transplantation Ag
Antigens expressed on tumour cells
Tumor Associated Developmental
7/29/2019 Cancer and the Immune System_BS963_EK
33/44
Tumor-Associated Developmental
Antigens
Found on cancer cells and on fetal cells.
Do not trigger anti-tumor immunity.
Used in diagnosis.Alpha-fetoprotein(AFP)
Cancers of liver
Carcinoembryonic Ag (CEA)colorectal cancer
Identification of tumour antigens
7/29/2019 Cancer and the Immune System_BS963_EK
34/44
Identification of tumour antigens
Use the immune system as a tool forthe identification of
immunogenic antigens
Gene profiling genomics or transciptomics
Proteomic approaches
peptidomics, serum profiling
In-silico bioinformatic approaches
probing EST databases
O h T i d i
7/29/2019 Cancer and the Immune System_BS963_EK
35/44
Other Tumor associated antigensShared tumour antigens: common in different tumours
Cancer-testis antigensMAGE family etc.
Differentiation antigens
Melan-A/MART-1, gp100
Over-expressed proto-oncogenesHER2/neu, WT1
Some additional antigens
MUC-1 (over-expressed)
Unique tumour antigens
Point mutations: p53, Raf, Bcr/Abl
viral antigens: HPV, EBV etc.
7/29/2019 Cancer and the Immune System_BS963_EK
36/44
5. How do tumour cells escape
from the immune system?
7/29/2019 Cancer and the Immune System_BS963_EK
37/44
Malignant cells can be controlled by
immunosurveillance
NK Natural Killers
CD4, CD8 and gd types of T-lymphocytes
7/29/2019 Cancer and the Immune System_BS963_EK
38/44
7/29/2019 Cancer and the Immune System_BS963_EK
39/44
6. Anti-tumour therapy.
Anti-tumour vaccines.
7/29/2019 Cancer and the Immune System_BS963_EK
40/44
Ideal tumour antigen:
- displays tumour-specificexpression
- is immunogenic
- plays an important functional rolein cell survival / differentiation /
metastasis etc.
7/29/2019 Cancer and the Immune System_BS963_EK
41/44
Specific
Active Immunization: Vaccination with viral
Antigens: e.g.
Hepatitis B virus
Human Papilloma virus (HPV) success
story.
Ab Therapy
Abs specific for oncogene product e.g. Abs
against HER2/neu (Herceptin ortrastuzumab)
Anti-tumour therapy
7/29/2019 Cancer and the Immune System_BS963_EK
42/44
7/29/2019 Cancer and the Immune System_BS963_EK
43/44
Nonspecific:
BCG (Bacillus Calmette-Guerin) Mycobacteria
used as an adjuvant - melanoma, bladdercarcinoma
Irradiated tumour cells ( with or without BCG)
Normal
Macro
phage
Tumor
Activated
Macro
phage
Tumor
lysis
Ad ti i th
7/29/2019 Cancer and the Immune System_BS963_EK
44/44
Adoptive immunotherapyex vivo manipulation and transfer of effector cells
- Antibody-Dependent Cellular Cytotoxicity (ADCC)
Gene therapy
Introduce cytokine genes for IL-2, IL-4, IL-12, IFN-g etc into tumor cells toinduce immune response.
tumour T cell
IL-2
IFN-g